Related Experiment Videos
Intralesional interferon in basal cell carcinoma: how does it work?
Stanislaw Buechner1, Marion Wernli, Felix Bachmann
1Department of Dermatology, University of Basel, Kantonsspital, Switzerland.
Summary
Interferon alpha (IFN alpha) treats basal cell carcinoma (BCC) by making cancer cells express CD95 receptors, leading to their self-destruction. This mechanism helps overcome immune evasion in BCC treatment.
Area of Science:
- Immunology
- Dermatology
- Oncology
Background:
- Basal cell carcinoma (BCC) is the most common skin cancer, with increasing incidence.
- Intralesional interferon alpha (IFN alpha) is a recognized treatment for BCC.
- The precise mechanism of IFN alpha's action on BCC requires further elucidation.
Purpose of the Study:
- To investigate the mechanism by which IFN alpha induces regression of basal cell carcinoma.
- To identify the role of the CD95 receptor-ligand system in BCC treatment response.
Main Methods:
- Analysis of CD95 ligand (CD95L) and CD95 receptor expression in BCC cells from untreated and IFN alpha-treated patients.
- Assessment of BCC cell apoptosis and lysis in response to CD95 pathway activation.
- Evaluation of peritumoral infiltrating cells and cytokine profiles.
Main Results:
- Untreated BCC cells express CD95L but not the CD95 receptor, enabling immune evasion.
- IFN alpha treatment induces CD95 receptor expression on BCC cells.
- BCC cells undergo apoptosis and lysis via CD95 receptor-CD95L interaction (fratricide) upon IFN alpha treatment.
- Peritumoral CD4+ T cells and cytokines like IFN gamma may contribute to BCC regression by upregulating CD95.
Conclusions:
- IFN alpha treatment redirects BCC cells towards apoptosis through the CD95 pathway.
- The CD95 system plays a critical role in the therapeutic efficacy of IFN alpha for BCC.
- Understanding this mechanism may inform future therapeutic strategies for skin cancer.